About Us
Innovate and forge ahead with leading original products in the industry
About Us
/
Enterprise Development
December 2023
December 2023

Exciting News | CytoNiche Biotech Honored on Deloitte's "China Pharmaceutical and Health Tomorrow Star" List.

November 2023
November 2023

3D TableTrix® G Series microcarrier, Focused on the gene therapy.

November 2023
November 2023

The 3D FloTrix® vivaFILL cell filling system is dedicated to the filling of "live" cell preparations. It focuses on various cell formulations and extracellular vesicle formulations, ensuring the effic

November 2023
November 2023

The world's first stem cell-based new drug, utilizing the Cytoniche's 3D FloTrix® process, has been accepted by the China Drug Evaluation (CDE).

September 2023
September 2023

As a key unit of the association, Cytoniche actively participated in the drafting of the "Quality Management Specification for Raw Materials Used in the Production of Cell Therapy Products" (Group Sta

September 2023
September 2023

Cytoniche's【3D FloTrix® Billion-Scale Process】 for the preparation of human umbilical cord mesenchymal stem cells has once again received authoritative third-party quality certification (Number: Inspe

September 2023
September 2023

Cytoniche's 3D microcarrier achieves authoritative certification from the China National Institute for Food and Drug Control (NIFDC) for the fully closed-scale preparation of human umbilical cord mese

August 2023
August 2023

The 3D RecomTrix® recombinant collagen microcarrier retains the core features of the 3D TableTrix® microcarrier. The unique difference lies in the fact that it is composed of non-animal sourced recomb

July 2023
July 2023

The 3D TableTrix® V Series microcarrier ,Focused on the vaccine field.

July 2023
July 2023

3D TableTrix® Microcarriers developed by CytoNiche has been filed with FDA-MF (MF: 29721)

July 2023
July 2023

3D TableTrix® Microcarriers developed by CytoNiche has been filed with FDA-DMF (DMF: 037798)

June 2023
June 2023

3D FloTrix® mesenchymal stem cell serum-free medium developed by CytoNiche has been filed with FDA DMF (DMF: 038476).

May 2023
May 2023

CytoNiche made the list of the "2023 Future Healthcare 100" series

May 2023
May 2023

CytoNiche International Center for Cooperation and Technology Application was established

May 2023
May 2023

3D FloTrix®vivaPACK Cell Filling System effectively completes the packaging of cell preparations, enabling the filling process of more than 100 bags of various cell fully enclosed preparations

March 2023
March 2023

3D FloTrix®vivaPREP PLUS Cell Harvesting System provides efficient cell production and preparation to support the cell therapy industry

February 2023
February 2023

CytoNiche has been honored on the "Science and Technology in China" Pilot Technology List by the China Association for Science and Technology

February 2023
February 2023

CytoNiche makes the top 100 list

December 2022
December 2022

CytoNiche selected as 2021 GEI China Potential Unicorn

November 2022
November 2022

Approved to set up a postdoctoral scientific research workstation

August 2022
August 2022

3D FloTrix® Cell CDMO platform was officially unveiled, and the expansion of the Beijing headquarters was completed

August 2022
August 2022

Topped the list of medical enterprises with 10 times growth potential of 36 krypton

June 2022
June 2022

Listed in KPMG China's first Biotechnology Innovation 50 Enterprise List

April 2022
April 2022

Tsinghua University & Huakan Biology's original research technology won the Geneva Invention Gold Medal

March of the same year
March of the same year

3D FloTrix® Microcarriers for Vaccines Launched

March 2022
March 2022

Completed nearly 300 million yuan in round B financing, accelerating the industrialization of 3D cell "smart manufacturing"

February 2022
February 2022

Tianjin GMP production platform expanded to 4000 square meters, new 1200L microcarrier production line

July 2021
July 2021

The cumulative annual sales exceeded 10 million yuan, and the financing of nearly 100 million yuan was completed

June 2021
June 2021

The GMP manufacturing platform was successfully certified by the ISO9001 and IS013485 quality management systems

April 2021
April 2021

3D TableTrix® Cell Microcarrier Tablet obtained the qualifications DMF for pharmaceutical excipients from the US FDA (DMF:35481)

February 2021
February 2021

3D TableTrix® Cell Microcarrier Tablet obtained two qualifications for pharmaceutical excipients from CDE (Filing No.:F20200000496/F20210000003)

December 2020
December 2020

3D TableTrix® microcarrier core products were released in United States, the European Union, Japan and other countries

October 2020
October 2020

3D FIoTrix@ VS series of pilot-scale production-grade bioreactors were officially released in the market

June 2020
June 2020

Proprietary products of 3D TableTrix® series of microcarrier tablet officially were officially released in the market

January 2020
January 2020

The certification of intellectual property management system was completed

October 2019
October 2019

followed by A GMP-certified manufacturing base of 2000 square meters launched in the next month.

December 2019
December 2019

The application for "Zhongguancun Subversive Project" was successful; the certification of "National High-tech Enterprise" was obtained and the company ranked among top 3 in "Global Entrepreneurship World Cup" at the same time

March 2019
March 2019

In March 2019, Cytoniche received angel fund and a R&D center of 1500 square meters was therefore launched.

2018
2018

In 2018, the technology was successfully translated into Beijing CytoNiche Biotechnology Co., Ltd., joined by Tsinghua University equity-wise.

<br>

After more than 10 years of research in the field of cell microcarriers, Professor Du Yanan of Tsinghua University along with his research team have published a number of international leading research achievements internationally


Copyright: Beijing CytoNiche Biotechnology Co., Ltd.
Copyright: Beijing CytoNiche Biotechnology Co., Ltd.